Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review

4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors

(2010) Kevin K.-C. Liu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα

(2010) David J. Richard et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability

(2010) Jeroen C. Verheijen et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment

(2010) Carlos García-Echeverría   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors

(2010) Arie Zask et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer

(2010) Qingsong Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor

(2010) Aranapakam M. Venkatesan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

(2010) Hengmiao Cheng et al.   MedChemComm

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

(2010) Steven D. Knight et al.   ACS Medicinal Chemistry Letters

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Discovery of 4-Morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as Highly Potent and Selective ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR): Optimization of the 6-Aryl Substituent

(2009) Jeroen C. Verheijen et al.   JOURNAL OF MEDICINAL CHEMISTRY

ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines

(2009) Arie Zask et al.   JOURNAL OF MEDICINAL CHEMISTRY

Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors

(2009) Arie Zask et al.   JOURNAL OF MEDICINAL CHEMISTRY

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY